by John A. Jenkins | May 14, 2026 | FOIA, Litigation, Pharmaceuticals, SEC
FOIAengine: Requests to SEC Preceded Stock Troubles and a Surprise Resignation For a company that most Americans have never heard of, Medpace Holdings, Inc. (NASD:MEDP) sits remarkably close to the center of the modern drug-development economy. The Cincinnati-based...
by John A. Jenkins | Apr 9, 2026 | FDA, FOIA, Litigation, Medical Devices, Short-Selling, Stock Market
How FOIA Requests Signaled Problems With a “Bionic Pancreas” At a federal advisory panel meeting in 2018, a biomedical engineer named Ed Damiano stepped to the microphone – not just as a scientist. “I’m also a father,” he told regulators, describing his son’s...
by John A. Jenkins | Apr 1, 2026 | FDA, FOIA
FOIAengine: Advocates on Both Sides Push FDA for Data as a Senate Investigation Begins Even before Sen. Josh Hawley (R-Mo.) walked into a March 11 news conference to kick off an effort to ban the abortion drug mifepristone as unsafe – and days before he opened an...
by John A. Jenkins | Mar 26, 2026 | FDA, FOIA
FOIAengine: How FOIA Requests Pointed to Problems at Boston Scientific Months before Boston Scientific expanded its urgent warning this month about the risk of sudden death from its Accolade pacemakers, something quieter was happening inside the U.S. Food and Drug...
by John A. Jenkins | Mar 11, 2026 | DOJ, FOIA, Politics, SEC
FOIAengine: How a Grassroots Movement Saw New Evidence of a Conspiracy In December, a retired California Highway Patrol officer named Wilma Stone filed an unusual Freedom of Information Act request with the Securities and Exchange Commission. Stone asked the agency...
